Observational Study of Maribavir for Treating Cytomegalovirus Infection After Organ or Stem Cell Transplant in Adults in Belgium

What this Trial Is About

Cytomegalovirus CMV is a common virus that can cause serious illness in people with weakened immune systems, especially those who have undergone transplants. Researchers are evaluating the use of maribavir, a medicine approved for treating CMV infection in adults after transplant, to learn how safe and effective it is in adults with post-transplant CMV infection in Belgium according to Belgian reimbursement rules. This is a non-interventional observational study where participants with post-transplant CMV infection or disease, who are starting maribavir treatment for the first time in line with Belgian reimbursement criteria, will be observed. The study collects data prospectively for up to 2 years without fixed hospital visits, relying mainly on routine visits and contacts. Participants will have their medical and treatment data collected during routine care visits over 2 years. Researchers will monitor outcomes such as how many participants clear the CMV virus, treatment duration, time to viral clearance, drug resistance, recurrence after treatment, and any treatment-related adverse events. The study aims to reflect real-world use of maribavir in daily clinical practice.

A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium